Bemcentinib
http://dbpedia.org/resource/Bemcentinib an entity of type: Thing
Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.
rdf:langString
rdf:langString
Bemcentinib
xsd:integer
56244890
xsd:integer
1047963363
xsd:integer
30
xsd:integer
1037624
xsd:integer
34
xsd:integer
1
rdf:langString
D11438
rdf:langString
Investigational
xsd:integer
8
xsd:integer
46215462
rdf:langString
Nc1ncnn1-c1cc2c-c1ccccc1CCC2
xsd:integer
1
rdf:langString
KXMZDGSRSGHMMK-RUZDIDTESA-N
rdf:langString
BGB324; R428
xsd:integer
0
rdf:langString
Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.
xsd:nonNegativeInteger
5327
xsd:string
1037624-75-1
xsd:string
0ICW2LX8AS
xsd:string
D11438
xsd:string
46215462